Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Health, Eone-Diagnomics Genome Center Ink Liquid Biopsy Partnership

NEW YORK – Molecular Health said Wednesday that is collaborating with South Korea's Eone-Diagnomics Genome Center (EDGC) to create a combined offering for precision oncology testing.

Specifically, the companies are pairing Molecular Health’s MH Guide software and EDGC’s OncoCatch-CDx assay, which analyzes circulating tumor DNA using next-generation sequencing in-house bioinformatics.

A joint venture established in 2013, EDGC currently provides a variety of clinical and consumer genetics products and services in addition to liquid biopsy, including noninvasive prenatal testing, newborn genetic screening, and a direct-to-consumer assay called Gene2me that assesses patients' cancer risk status.

Under the partnership with Molecular Health, EDGC will utilize that firm's analysis software, which automatically identifies genetic variants that are relevant for the treatment of cancer patients, to support reporting of OncoCatch-CDx results to ordering clinicians.

Financial terms of the agreement were not disclosed.